Loading...
MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) incombination with pembrolizumab in pts with malignant mesothelioma
Krebs, Matthew G Carter, Louise Villa, Shaun King, A Massey, C Lorens, J Darlington, Emma Fennell, D
Krebs, Matthew G
Carter, Louise
Villa, Shaun
King, A
Massey, C
Lorens, J
Darlington, Emma
Fennell, D
Citations
Altmetric:
Abstract
Description
Date
2018
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Krebs M, Carter L, Villa S, King A, Massey C, Lorens J, et al. P2.06-09 MiST3: a phase II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with pembrolizumab in pts with malignant mesothelioma. J Thorac Oncol. 2018;13(10):S745.